Abstract Body

Background: Cryptococcal meningitis is a leading cause of death in people living with HIV/AIDS in sub-Saharan Africa. To decrease cryptococcosis, WHO recommends pre-antiretroviral (ART) targeted cryptococcal antigen (CrAg) screening for persons with CD4 < 100 cells/μL. Aiming to explore the potential impact of this strategy in Tanzania, we assessed the prevalence, natural course, and outcome of cryptococcal antigenemia in a rural region of southern Tanzania. Methodology: Retrospective study including all patients prospectively enrolled in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) with a pre-ART visit between Jan 1, 2007 and Dec 31, 2012. Cryopreserved pre-ART plasma samples of ART-naive patients > 5 years-old and with CD4 < 150 cells/μL were tested for CrAg using lateral flow assay kits. Logistic regression was used to estimate the association between CrAg+ and a composite outcome of death or lost to follow-up (LFU) after one-year follow-up. Results: Of 801 eligible patients, 29 (3.6%) were CrAg+, corresponding to 6.1% (18/293), 2.3% (6/263), and 2% (5/245) prevalence among patients with CD4 < 50, 51-100, and 101-150 cells/μL, respectively. ART was initiated in 686 (85.6%). Within one year, 72.4% (21/29) of CrAg+ patients died or were LFU compared with 47.2% (364/772) of CrAg-negative patients (p=0.008), with no differences across CD4 strata. After adjusting for age and gender, three independent predictors of death/LFU were identified: CrAg+ (odds ratio (OR) 3.2, 95% confidence interval (CI) 1.4-7.3, p=0.008), CD4 < 100 cells/μL (OR 1.6, 95% CI 1.1-2.2, p=0.006), and not having received ART (OR 7.7, 95% CI 4.5-13.2, p<0.001). The median pre-ART CrAg titre among CrAg+ patients was 1:320 (interquartile range 1:20, 1:2560). Cryptococcal meningitis was diagnosed in 34% (10/29) of CrAg+ patients, and the remainder (19/29) showed no pre-ART neurological symptoms, with similar outcome between both groups (70% vs. 74% death/LFU respectively, p=0.8). Fluconazole given at physician discretion decreased the proportion of death/LFU among CrAg+ patients (80% without treatment, 60% with 100-200 mg daily, and none with 800 mg daily, p=0.012). Conclusions: CrAg+ was prevalent and an independent predictor of death/LFU. Targeted pre-ART CrAg screening may decrease early ART-mortality in Tanzania. However, a threshold for CrAg screening at CD4 < 100 cells/μL, according to WHO recommendations, may exclude a substantial number of CrAg+ patients and decrease the potential impact of this strategy.